NCT05585567 (COVID-19) is a EARLY_PHASE1 clinical trial of V-01/V-01-B5 in COVID-19 Pandemic, sponsored by Livzon Pharmaceutical Group Inc..

Who is sponsoring NCT05585567?

NCT05585567 is sponsored by Livzon Pharmaceutical Group Inc..

What drugs are being tested in NCT05585567?

Interventions in NCT05585567: V-01/V-01-B5, V-01-351/V-01-B5, V-01.

What condition does NCT05585567 study?

NCT05585567 studies COVID-19 Pandemic.

Is NCT05585567 still recruiting?

NCT05585567 is currently status unknown. Last updated 7 November 2022.

Last reviewed 2022-11-07 · How we verify

NCT05585567: COVID-19

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

A Preliminary Exploratory Study to Evaluate the Safety and Immunogenicity of Omicron Variant Bivalent Vaccine V-01-B5

Status unknown EARLY_PHASE1 Last updated 7 November 2022

What this trial tests

EARLY_PHASE1 trial testing V-01/V-01-B5 in COVID-19 Pandemic in 48 participants. Status unknown.

Timeline

16 September 2022

Primary endpoint
14 October 2022

11 September 2023

Quick facts

Lead sponsor	Livzon Pharmaceutical Group Inc.
Phase	EARLY_PHASE1
Status	Status unknown
Study type	INTERVENTIONAL
Allocation	randomized
Design	crossover
Masking	none
Primary purpose	prevention
Enrollment	48
Start date	16 September 2022
Primary completion	14 October 2022
Estimated completion	11 September 2023
Sites	1 location across China

Drugs / interventions tested

V-01/V-01-B5 — full drug profile →
V-01-351/V-01-B5 — full drug profile →
V-01 — full drug profile →

Conditions studied

COVID-19 Pandemic — all drugs for COVID-19 Pandemic →

Sponsor

Livzon Pharmaceutical Group Inc. — full company profile →

Who can join

Adults 18 to 59, any sex, with COVID-19 Pandemic. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

It is a single center, randomized, open-labeled, exploratory clinical study to evaluate the safety and immunogenicity of Recombinant SARS-CoV-2 Fusion Protein bivalent Vaccine V-01-B5 as a second booster in adults aged 18-59 years after vaccinated with 3-dose of inactivated vaccines.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

The Bivalent COVID-19 Booster Immunization after Three Doses of Inactivated Vaccine Augments the Neutralizing Antibody Response against Circulating Omicron Sublineages.
He Q, Sun S, Chen X, Hu Z, et al · · 2022 · cited 9× · PMID 36614948 · DOI 10.3390/jcm12010146

Verify or expand the search:

Other recruiting trials for COVID-19 Pandemic

Currently open trials in the same condition.

NCT05825651 — Long COVID and Its Associations With Health Outcomes in Older Adults · active not recruiting
NCT06927622 — Corona Virus Disease 2019 Cohort Study · recruiting
NCT05096260 — Getting to Yes, Michigan! (G2YMI) · NA · active not recruiting
NCT06208943 — Neural and Cognitive Consequences of COVID-19 Survival · recruiting

Other Livzon Pharmaceutical Group Inc. trials

Trials by the same sponsor.

NCT06963320 — Phase II Clinical Study of H001 Capsule in the Prevention of Venous Thromboembolism After Total Knee Arthroplasty · Phase 2 · recruiting
NCT06850480 — A Phase III Clinical Trial for Efficacy and Safety Evaluation of JP-1366 Tablets on Reflux Esophagitis · Phase 3 · recruiting
NCT05583357 — Exploratory Clinical Study to Evaluation of the Safety and Immunogenicity of Bivalent Vaccine V-01D-351 · EARLY_PHASE1 · unknown
NCT05273528 — The Immunogenicity and Safety of V-01-351/V-01D Bivalence Vaccine · Phase 2 · unknown
NCT05238649 — Immunogenicity and Safety of Sequential Immunization of Recombinant SARS-CoV-2 Fusion Protein Vaccine · Phase 2 · unknown

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05585567 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Livzon Pharmaceutical Group Inc.
Last refreshed: 7 November 2022

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05585567.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing